Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2009

Open Access 01-12-2009 | Review

Recent advances of novel targeted therapy in non-small cell lung cancer

Authors: Jed A Katzel, Michael P Fanucchi, Zujun Li

Published in: Journal of Hematology & Oncology | Issue 1/2009

Login to get access

Abstract

Lung cancer is the leading cause of cancer deaths world-wide. Recent advances in cancer biology have led to the identification of new targets in neoplastic cells and the development of novel targeted therapies. At this time, two targeted agents are approved by the FDA in advanced non-small cell lung cancer (NSCLC): the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib, and the anitangiogenic bevacizumab. A third agent, cetuximab, which was recently shown to enhance survival when used with cisplatin and vinorelbine as first line therapy for advanced NSCLC, will likely be approved by regulatory agencies. With more than 500 molecularly targeted agents under development, the prospects of identifying novel therapies that benefit individual patients with lung cancer are bright.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Muray T, Thun MJ: Cancer Statistics, 2008. Ca Cancer J Clin. 2008, 58: 71-96. 10.3322/CA.2007.0010.PubMedCrossRef
2.
Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. Ca Cancer J Clin. 2005, 55: 74-108.PubMedCrossRef
3.
Weinberg RA: Growth factor receptors can function as oncoproteins. The biology of cancer. Edited by: Elizabeth Zayatz. 2007, New York: Garland Science, 129-131. 1
4.
Sporn MB, Todaro GJ: Autocrine secretion and malignant transformation of cells. N Engl J Med. 1980, 303: 878-80.PubMedCrossRef
5.
Citri A, Yarden Y: EGF-ERBB signaling: towards the systems level. Nat Rev Mol Cell Biol. 2006, 7: 505-16. 10.1038/nrm1962.PubMedCrossRef
6.
Hynes NH, Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005, 5: 341-54. 10.1038/nrc1609.PubMedCrossRef
7.
Fukuoka M, Yano S, Giaccone G, Tumura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Badelga J: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (the IDEAL 1 Trial). J Clin Oncol. 2003, 21: 2237-2246. 10.1200/JCO.2003.10.038.PubMedCrossRef
8.
Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC: Efficacy of gefitinib, and inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003, 290: 2149-2158. 10.1001/jama.290.16.2149.PubMedCrossRef
9.
Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005, 366: 1527-1537. 10.1016/S0140-6736(05)67625-8.PubMedCrossRef
10.
Crinò L, Cappuzzo F, Zatloukal P, Reck M, Pesek M, Thompson JC, Ford HE, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Duffield EL, Armour AA, Speake G, Cullen M: Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol. 2008, 26: 4253-4260. 10.1200/JCO.2007.15.0672.PubMedCrossRef
11.
Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabárbara P, Bonomi P: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004, 22: 3238-3247. 10.1200/JCO.2004.11.057.PubMedCrossRef
12.
Perez-Soler R: Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non small-cell lung cancer. Clin Lung Cancer. 2004, 6 (Suppl 1): S20-S23. 10.3816/CLC.2004.s.010.PubMedCrossRef
13.
Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A: Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005, 23: 2544-2555. 10.1200/JCO.2005.02.477.PubMedCrossRef
14.
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L, National Cancer Institute of Canada Clinical Trials Group: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005, 353: 123-132. 10.1056/NEJMoa050753.PubMedCrossRef
15.
Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J: Prospective randomized trial of docetaxel versus best supportive care in patients with nonsmall-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000, 18: 2095-2103.PubMed
16.
Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M, Ayoub J, Lago S, de Albuquerque Ribeiro R, Gerogianni A, Cyjon A, Noble J, Laberge F, Chan RT, Fenton D, von Pawel J, Reck M, Shepherd FA, National Cancer Institute of Canada Clinical Trials Group Study BR.21: Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the national cancer institute of Canada clinical trials group study BR.21. J Clin Oncol. 2006, 24: 3831-3837. 10.1200/JCO.2006.05.8073.PubMedCrossRef
17.
Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH: Gefitinib in combination with gemcitabine and cisplatin in advanced non small-cell lung cancer: a phase III trial – INTACT 1. J Clin Oncol. 2004, 22: 777-784. 10.1200/JCO.2004.08.001.PubMedCrossRef
18.
Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH: Gefitinib in combination with paclitaxel and carboplatin in advanced nonsmall-cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol. 2004, 22: 785-794. 10.1200/JCO.2004.07.215.PubMedCrossRef
19.
Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA, TRIBUTE Investigator Group: TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005, 23: 5892-5899. 10.1200/JCO.2005.02.840.PubMedCrossRef
20.
Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, Milanowski J, Karnicka-Mlodkowski H, Pesek M, Serwatowski P, Ramlau R, Janaskova T, Vansteenkiste J, Strausz J, Manikhas GM, Von Pawel J: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007, 25: 1545-1552. 10.1200/JCO.2005.05.1474.PubMedCrossRef
21.
Gandara DR, Gumerlock PH: Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case close or is the jury still out?. J Clin Oncol. 2005, 25: 5856-5858. 10.1200/JCO.2005.05.030.CrossRef
22.
Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, Jänne PA: Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res. 2004, 64: 7241-7244. 10.1158/0008-5472.CAN-04-1905.PubMedCrossRef
23.
Shepherd FA: Molecular selection of patients for first-line treatment of advanced non-small-cell lung cancer with epidermal growth factor inhibitors: not quite ready for prime time. J Clin Oncol. 2008, 26: 2426-2427. 10.1200/JCO.2007.15.4286.PubMedCrossRef
24.
Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA, Poplin EA, Hidalgo M, Baselga J, Clark EA, Mauro DJ: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007, 25: 3230-3237. 10.1200/JCO.2006.10.5437.PubMedCrossRef
25.
Van Cutsem E, Lang I, D'haens G, Moiseyenko V, Zaluski J, Folprecht G, Tejpar S, Kisker O, Stroh C, Rougier P: KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI without or without cetuximab [abstract]. J Clin Oncol. 2008, 26 (Suppl 15): 2-
26.
Bokemeyer C, Bondarenko I, Hartmann JT, De Braud FG, Volovat C, Nippgen J, Stroh C, Celik I, Koralewski P: KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer with FOLFOX with or without cetuximab: the OPUS experience [abstract]. J Clin Oncol. 2008, 26 (Suppl 15): 4000-
27.
Lacouture ME: Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006, 6: 803-812. 10.1038/nrc1970.PubMedCrossRef
28.
Clynes RA, Towers TL, Presta LG, Ravetch JV: Inhibitory Fc receptors modulate in vivo cytotoxicty against tumor targets. Nature Med. 2000, 6: 443-446. 10.1038/74704.PubMedCrossRef
29.
Rossi A, Maione P, Gridelli C: Cetuximab in advanced non-small-cell lung cancer. Crit Rev Oncol Hematol. 2006, 59: 139-49. 10.1016/j.critrevonc.2006.02.006.PubMedCrossRef
30.
Herbst RS, Chansky K, Kelly K, Atkins JN, Davies AM, Dakhil SR, Albain KS, Kim ES, Crowley JJ, Gandara DR: A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced nonsmall cell lung cancer (NSCLC): final report of SWOG 0342 [abstract]. J Clin Oncol. 2007, 25 (Suppl 18): 7545-
31.
Belani CP, Ramalingam S, Schreeder M, Steis R, Guidice R, Marshland T, Butler B: Phase II study of cetuximab in combination with carboplatin and docetaxel for patients with advanced/metastatic non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2007, 25 (Suppl 18): 7643-
32.
Butts CA, Bodkin D, Middleman EL, Englund CW, Ellison D, Alam YZ, Pautret V, Weber M, Kreisman H, Shepherd FA: Gemcitabine/platinum alone or in combination with cetuximab as first-line treatment for advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2007, 25 (Suppl 18): 7539-
33.
Rosell R, Robinet G, Szczesna A, Ramlau R, Constenla M, Mennecier BC, Pfeifer W, O'Byrne KJ, Welte T, Kolb R, Pirker R, Chemaissani A, Perol M, Ranson MR, Ellis PA, Pilz K, Reck M: Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol. 2008,
34.
Pirker R, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Park K, Gatzemeier U, Bajeta E, Emig M, Pereira JR: FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2008, 26 (Suppl 15): 3-10.1200/JCO.2008.16.1190.CrossRef
35.
Non-small cell lung cancer, clinical practice guidelines in oncology (version 1.2009). ©2006 National Comprehensive Cancer Network, Inc, , [http://​www.​nccn.​org]
36.
Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D'Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H, Mendelsohn J: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 2000, 18: 904-914.PubMed
37.
Freeman D, Sun J, Bass R, Jung K, Ogbagabriel S, Elliott G, Radinsky R: Panitumumab and cetuximab epitope mapping and in vitro activity [abstract]. J Clin Oncol. 2008, 26 (Suppl 15): 14536-
38.
Schmiedel J, Blaukat A, Li S, Knöchel T, Ferguson KM: Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell. 2008, 13: 365-373. 10.1016/j.ccr.2008.02.019.PubMedCentralPubMedCrossRef
39.
Weiner LM, Belldegrun A, Rowinsky E, Crawford J, Lockbaum P, Huang S, Arends R, Schwab G, Figlin R: Updated results from a dose and schedule study of panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies [abstract]. J Clin Oncol. 2005, 23 (Suppl 16): 3059-
40.
Socinski MA: Antibodies to the epidermal growth factor receptor in non-small cell lung cancer: current status of matuzumab and panitumumab. Clin Cancer Res. 2007, 13 (Suppl 15): 4597-4601. 10.1158/1078-0432.CCR-07-0335.CrossRef
41.
Crawford J, Sandler AB, Hammond LA, Schiller J, Belani C, Kozloff M, Johnson D, Fleishman A, Lee S, Takeshita K: ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2004, 22 (Suppl 14): 7083-
42.
Vanhoefer U, Tewes M, Rojo F, Dirsch O, Schleucher N, Rosen O, Tillner J, Kovar A, Braun AH, Trarbach T, Seeber S, Harstrick A, Baselga J: Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol. 2004, 22: 175-184. 10.1200/JCO.2004.05.114.PubMedCrossRef
43.
Kollmannsberger C, Schittenhelm M, Honecker F, Tillner J, Weber D, Oechsle K, Kanz L, Bokemeyer C: A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2006, 17: 1007-1013. 10.1093/annonc/mdl042.PubMedCrossRef
44.
Salazar R, Tabernero J, Rojo F, Jimenez E, Montaner I, Casado E, Sala G, Tillner J, Malik R, Baselga J: Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD) [abstract]. J Clin Oncol. 2004, 22 (Suppl 14): 2002-
45.
Rivera F, Vega-Villegas ME, Lopez-Brea MF, Marquez R: Current situation of panitumumab, matuzumab, nimotuzumab and zalutumumab. Acta Oncol. 2008, 47: 9-19. 10.1080/02841860701704724.PubMedCrossRef
46.
Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ: Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res. 2007, 13: 3913-3921. 10.1158/1078-0432.CCR-06-2610.PubMedCrossRef
47.
Testa JR, Siegfried JM: Chromosome abnormalities in human non-small cell lung cancer. Cancer Res. 1992, 52 (Suppl 9): 2702s-2706s.PubMed
48.
Sharma SV, Bell DW, Settleman J, Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007, 7: 169-181. 10.1038/nrc2088.PubMedCrossRef
49.
Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004, 64: 8919-8923. 10.1158/0008-5472.CAN-04-2818.PubMedCrossRef
50.
Janne PA, Engelman JA, Johnson BE: Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol. 2005, 23: 3227-3234. 10.1200/JCO.2005.09.985.PubMedCrossRef
51.
Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R, Buttitta F: EGFR mutations in non-small-cell lung caner: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005, 23: 857-865. 10.1200/JCO.2005.08.043.PubMedCrossRef
52.
Sordella R, Bell DW, Haber DA, Settleman J: Gefitinib-sensitizing EGFR mutations in lugn cancer activate anti-apoptotic pathways. Science. 2004, 305: 1163-1167. 10.1126/science.1101637.PubMedCrossRef
53.
Jiang J, Greulich H, Jänne PA, Sellers WR, Meyerson M, Griffin JD: Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib sensitive cell cycle progression. Cancer Res. 2005, 65: 8968-8974. 10.1158/0008-5472.CAN-05-1829.PubMedCrossRef
54.
Predkin L, Wistuba LL: Epidermal growth factor receptor abnormalities in lung cancer. Pathogenic and clinical implications. Ann Diagn Pathol. 2006, 10: 306-315. 10.1016/j.anndiagpath.2006.06.011.CrossRef
55.
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004, 350: 2129-2139. 10.1056/NEJMoa040938.PubMedCrossRef
56.
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004, 304: 1497-1500. 10.1126/science.1099314.PubMedCrossRef
57.
Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004, 101: 13306-13311. 10.1073/pnas.0405220101.PubMedCentralPubMedCrossRef
58.
Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA: Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol. 2005, 23: 8081-8092. 10.1200/JCO.2005.02.7078.PubMedCrossRef
59.
Sequist LV, Bell DW, Lynch TJ, Haber DA: Molecular predictors of response to epidermal growth factor receptor antagonsits in non-small-cell lung cancer. J Clin Oncol. 2007, 25: 587-595. 10.1200/JCO.2006.07.3585.PubMedCrossRef
60.
Hirsch FR, Dziadziuszko R, Varella-Garcia M, Franklin WA, Gandara DR, Bunn PA: First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay. J Thorac Oncol. 2008, 3 (Suppl 2): S138-S142.PubMedCrossRef
61.
Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA: Erlotinib in lung cancer – molecular and clinical predictors of outcome. N Engl J Med. 2005, 353: 133-144. 10.1056/NEJMoa050736.PubMedCrossRef
62.
Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA, Varella-Garcia M: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005, 97: 643-655.PubMedCrossRef
63.
Hirsch FR, Varella-Garcia M, Bunn PA, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison G, Donald E, Knight L, Parums D, Botwood N, Holloway B: Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non small-cell lung cancer. J Clin Oncol. 2006, 24: 5034-5042. 10.1200/JCO.2006.06.3958.PubMedCrossRef
64.
Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N, Jiang H, Watkins C, Armour A, Masahiro Fukuoka: Phase III, randomised, open-label, first-line study of gefitinib (g) vs carboplatin/paclitaxel (c/p) in clinically selected patients with advanced non-small-cell lung cancer (NSCLC) (IPASS) [abstract]. Ann Oncol. 2008, 19 (Suppl 8): LBA2-
65.
Mok TS, Leong S, Liu X, Ichinose Y, Sriuranpong V, Liam C, Chen Y, Duffield E, Rukazenkov Y, Fukuoka M: Gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected chemonaïve patients (pts) with advanced non-small-cell lung cancer (NSCLC) in Asia (IPASS): randomized, open-label, phase III study. Chicago Multidisciplinary symposium in thoracic oncology 2008: 13–15 November 2008; Chicago. 2008, 100-
66.
Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomized phase III trial. Lancet. 2008, 372: 1809-1818. 10.1016/S0140-6736(08)61758-4.PubMedCrossRef
67.
Kelly K, Huang C: Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor. J Thorac Oncol. 2008, 3: 664-673. 10.1097/JTO.0b013e3181758141.PubMedCrossRef
68.
Dziadziuszko R, Witta SE, Cappuzzo F, Park S, Tanaka K, Danenberg PV, Barón AE, Crino L, Franklin WA, Bunn PA, Varella-Garcia M, Danenberg KD, Hirsch FR: Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. Clin Cancer Res. 2006, 12: 3078-3084. 10.1158/1078-0432.CCR-06-0106.PubMedCrossRef
69.
Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS: K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer. 2006, 8: 30-38. 10.3816/CLC.2006.n.030.PubMedCrossRef
70.
Husgafvel-Pursiainen K, Hackman P, Ridanpää M, Anttila S, Karjalainen A, Partanen T, Taikina-Aho O, Heikkilä L, Vainio H: K-ras mutations in human adenocarcinoma of the lung: association with smoking and occupational exposure to asbestos. Int J Cancer. 1993, 53: 250-256. 10.1002/ijc.2910530213.PubMedCrossRef
71.
Ahrendt SA, Decker PA, Alawi EA, Zhu Yr YR, Sanchez-Cespedes M, Yang SC, Haasler GB, Kajdacsy-Balla A, Demeure MJ, Sidransky D: Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer. 2001, 92: 1525-1530. 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H.PubMedCrossRef
72.
Soung YH, Lee JW, Kim SY, Seo SH, Park WS, Nam SW, Song SY, Han JH, Park CK, Lee JY, Yoo NJ, Lee SH: Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch. 2005, 446: 483-488. 10.1007/s00428-005-1254-y.PubMedCrossRef
73.
Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Jänne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005, 23: 5900-5909. 10.1200/JCO.2005.02.857.PubMedCrossRef
74.
Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, Zhang T, Marrano P, Whitehead M, Squire JA, Kamel-Reid S, Seymour L, Shepherd FA, Tsao MS, National Cancer Institute of Canada Clinical Trials Group Study BR.21: Role of KRAS and EGFR as biomarkers of response to erlotinib in national cancer institute of Canada clinical trials group study BR.21. J Clin Oncol. 2008, 26: 4268-4275. 10.1200/JCO.2007.14.8924.PubMedCrossRef
75.
Hirsch FR, Varella-Garcia M, Dziadziuszko R, Xiao Y, Gajapathy S, Skokan M, Lin M, O'Neill V, Bunn PA: Fluorescence in situ hybridization subgroup analysis of tribute, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer. Clin Cancer Res. 2008, 14: 6317-6323. 10.1158/1078-0432.CCR-08-0539.PubMedCentralPubMedCrossRef
76.
77.
Kelly K, Huang C: Biologic agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor. J Thorac Oncol. 2008, 3: 664-673. 10.1097/JTO.0b013e3181758141.PubMedCrossRef
78.
Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005, 352: 786-792. 10.1056/NEJMoa044238.PubMedCrossRef
79.
Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2: 225-234. 10.1371/journal.pmed.0020225.CrossRef
80.
Blencke S, Zech B, Engkvist O, Greff Z, Orfi L, Horváth Z, Kéri G, Ullrich A, Daub H: Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem Biol. 2004, 11: 691-701. 10.1016/j.chembiol.2004.02.029.PubMedCrossRef
81.
Elkind NB, Szentpétery Z, Apáti A, Ozvegy-Laczka C, Várady G, Ujhelly O, Szabó K, Homolya L, Váradi A, Buday L, Kéri G, Német K, Sarkadi B: Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD Gefitinib). Cancer Res. 1839, 65: 1770-1777. 10.1158/0008-5472.CAN-04-3303.CrossRef
82.
Reily GJ: Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. J Thorac Oncol. 2008, 3 (Suppl 2): S146-S149.CrossRef
83.
Sequist LV: Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Oncologist. 2007, 12: 325-330. 10.1634/theoncologist.12-3-325.PubMedCrossRef
84.
Gendreau SB, Ventura R, Keast P, Laird AD, Yakes FM, Zhang W, Bentzien F, Cancilla B, Lutman J, Chu F, Jackman L, Shi Y, Yu P, Wang J, Aftab DT, Jaeger CT, Meyer SM, De Costa A, Engell K, Chen J, Martini JF, Joly AH: Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. Clin Cancer Res. 2007, 13: 3713-3723. 10.1158/1078-0432.CCR-06-2590.PubMedCrossRef
85.
Rizvi N, Kris M, Miller V, Krug L, Bekele S, Dowlati A, Rowland K, Tonda M, Mitchell B, Ruckdeschel J, Chaplen R, Aggarwal N, Gadgeel S: A phase II study of XL647 in Non-small cell lung cancer patients enriched for presence of EGFR mutations, AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. San Francisco, CA. 2007, B124-
86.
Spicer J, Calvert H, Vidal L, Azribi F, Perrett R, Shahidi M, Temple G, Futreal A, De Bono J, Plummer R: Activity of BIBW an oral irreversible dual EGFR/HER2 inhibitor, in non-small cell lung cancer with mutated EGFR. World Lung Cancer Congress. Seoul. 2992, D7-02.
87.
Erlichman C, Hidalgo M, Boni JP, Martins P, Quinn SE, Zacharchuk C, Amorusi P, Adjei AA, Rowinsky EK: Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol. 2006, 24: 2252-2260. 10.1200/JCO.2005.01.8960.PubMedCrossRef
88.
Harari D, Yarden Y: Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene. 2000, 19: 6102-6114. 10.1038/sj.onc.1203973.PubMedCrossRef
89.
Mounawar M, Mukeria A, Le Calvez F, Hung RJ, Renard H, Cortot A, Bollart C, Zaridze D, Brennan P, Boffetta P, Brambilla E, Hainaut P: Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. Cancer Res. 2007, 67: 5667-5672. 10.1158/0008-5472.CAN-06-4229.PubMedCrossRef
90.
Cohen EE, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM, Okimoto RA, Sgroi DC, Dahiya S, Muir B, Clark JR, Rocco JW, Vokes EE, Haber DA, Bell DW: Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res. 2005, 11: 8105-8108. 10.1158/1078-0432.CCR-05-0926.PubMedCrossRef
91.
Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H, Wistuba II, Fong KM, Toyooka S, Shimizu N, Fujisawa T, Minna JD, Gazdar AF: Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 2005, 65: 1642-1646. 10.1158/0008-5472.CAN-04-4235.PubMedCrossRef
92.
Zinner RG, Glisson BS, Fossella FV, Pisters KM, Kies MS, Lee PM, Massarelli E, Sabloff B, Fritsche HA, Ro JY, Ordonez NG, Tran HT, Yang Y, Smith TL, Mass RD, Herbst RS: Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer. 2004, 44: 99-110. 10.1016/j.lungcan.2003.09.026.PubMedCrossRef
93.
Langer CJ, Stephenson P, Thor A, Vangel M, Johnson DH, Eastern Cooperative Oncology Group Study 2598: Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol. 2004, 22: 1180-1187. 10.1200/JCO.2004.04.105.PubMedCrossRef
94.
Gatzemeier U, Groth G, Butts C, Van Zandwijk N, Shepherd F, Ardizzoni A, Barton C, Ghahramani P, Hirsh V: Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in Her2-positive non-small-cell lung cancer. Ann Oncol. 2004, 15: 19-27. 10.1093/annonc/mdh031.PubMedCrossRef
95.
Clamon G, Herndon J, Kern J, Govindan R, Garst J, Watson D, Green M, Cancer and Leukemia Group B: Lack of trastuzumab activity in non-small-cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. Cancer. 2005, 103: 1670-1675. 10.1002/cncr.20950.PubMedCrossRef
96.
Besse B, Ropert S, Soria JC: Targeted therapies in lung cancer. Annals Onc. 2007, 18: 135-142.CrossRef
97.
Janne PA, Schellens JH, Engelman JA, Eckhardt SG, Millham R, Denis LJ, Britten CD, Wong SG, Boss DS, Camidge DR: Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC [abstract]. J Clin Oncol. 2008, 26 (Suppl 15): 8027-
98.
Balsara BR, Pei J, Mitsuuchi Y, Page R, Klein-Szanto A, Wang H, Unger M, Testa JR: Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis. 2004, 25: 2053-2059. 10.1093/carcin/bgh226.PubMedCrossRef
99.
Bjornsti MA, Houghton PJ: The TOR pathway: a target for cancer therapy. Nature Rev Cancer. 2004, 4: 335-348. 10.1038/nrc1362.CrossRef
100.
Gridelli C, Maione P, Rossi A: The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist. 2008, 13: 139-147. 10.1634/theoncologist.2007-0171.PubMedCrossRef
101.
Molina JR, Mandrekar SJ, Rowland K, Reuter NF, Jett JR, Marks R, Schild SE, Adjei A: A phase II NCCTG "window of opportunity front-line" study of the mTOR inhibitor, CCI-779 (temosirolimus) given as a single agent in patients with advanced NSCLC. J Thorac Oncol. 2007, 2 (suppl 4): S413-10.1097/01.JTO.0000283298.56701.a0.CrossRef
102.
Papadimitrakopoulou V, Soria JC, Douillard JY, Giaccone G, Wolf J, Crino L, Cappuzzo F, Sharma S, Gross SH, Shepherd FA: A phase II study of RAD001 (r) (everolimus) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (c) or prior c and EGFR inhibitors (EGFR-I) [abstract]. J Clin Oncol. 2007, 25 (Suppl 18): 7589-
103.
Di Cosimo S, Matar P, Rojo F, Guzman M, Rodriguez S, Jimenez J, Arribas J, Cognetti F, Lane H, Baselga J: Schedule-dependent effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus (RAD001) [abstract]. J Clin Oncol. 2004, 22 (Suppl 14): 3074-
104.
Milton DT, Riely GJ, Azzoli CG, Gomez JE, Heelan RT, Kris MG, Krug LM, Pao W, Pizzo B, Rizvi NA, Miller VA: Phase 1 trial of everolimus and gefitinib in patients with advanced non small-cell lung cancer. Cancer. 2007, 110: 599-605. 10.1002/cncr.22816.PubMedCrossRef
105.
Papadimitrakopoulou V, Blumenschein GR, Leighl NB, Bennouna J, Soria JC, Burris HA, Dimitrijevic S, Kunz T, Di Scala L, Johnson BE: A phase I/II study investigating the combination of RAD001 (r) (everolimus) and erlotinib (e) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy I: phase I results [abstract]. J Clin Oncol. 2008, 26 (Suppl 15): 8051-
106.
Kumar Pal S, Figlin RA, Keckamp KL: The role of targeting mammalian target of rapamycin in lung cancer. Clin Lung Cancer. 2008, 9: 340-345. 10.3816/CLC.2008.n.049.CrossRef
107.
108.
Ferrara N: VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002, 2: 795-803. 10.1038/nrc909.PubMedCrossRef
109.
Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005, 23: 1011-27. 10.1200/JCO.2005.06.081.PubMedCrossRef
110.
Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, Sato M: Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family. Oncogene. 1990, 5: 519-524.PubMed
111.
Terman B: Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene. 1991, 6: 1677-1683.PubMed
112.
Paavonen K, Puolakkainen P, Jussila L, Jahkola T, Alitalo K: Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol. 2000, 156: 1499-1504.PubMedCentralPubMedCrossRef
113.
Hiratsuka S, Maru Y, Okada A, Seiki M, Noda T, Shibuya M: Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res. 2001, 61: 1207-1213.PubMed
114.
Fong GH, Rossant J, Gertsenstein M, Breitman ML: Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 1995, 376: 66-70. 10.1038/376066a0.PubMedCrossRef
115.
Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M: Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA. 1998, 95: 9349-9354. 10.1073/pnas.95.16.9349.PubMedCentralPubMedCrossRef
116.
Price DJ, Miralem T, Jiang S, Steinberg R, Avraham H: Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ. 2001, 12: 129-135.PubMed
117.
Fan F, Wey JS, McCarty MF, Belcheva A, Liu W, Bauer TW, Somcio RJ, Wu Y, Hooper A, Hicklin DJ, Ellis LM: Expression and function of vascular endothelial growth factor receptor 1 on human colorectal cancer cells. Oncogene. 2005, 24: 2647-2653. 10.1038/sj.onc.1208246.PubMedCrossRef
118.
Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004, 10: 145-147. 10.1038/nm988.PubMedCentralPubMedCrossRef
119.
Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005, 307: 58-62. 10.1126/science.1104819.PubMedCrossRef
120.
Jain RK, Munn LL: Vascular normalization as a rationale for combining chemotherapy with antiangiogenesis agents. Principles and Practice of Oncology Updates. 2007, 21: 1-7.
121.
Verheul HM, Lolkema MP, Qian DZ, Hilkes YH, Liapi E, Akkerman JW, Pili R, Voest EE: Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res. 2007, 13: 5341-10.1158/1078-0432.CCR-07-0847.PubMedCrossRef
122.
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med. 2006, 355: 2542-2540. 10.1056/NEJMoa061884.PubMedCrossRef
123.
124.
Manegold C, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsch V, Leighl N, Mezger J, Archer V, Reck M, the BO17704 study group: Randomized, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous no-small cell lung cancer (NSCLC): BO17704 [abstract]. J Clin Oncol. 2007, 25: 967s-
125.
Reck M, von Pawel J, Zatlouka P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Manegold C: First-line bevacizumab combined with cisplatin/gemcitabine (CG) in patients (PTS) with advanced non-small cell lung cancer (NSCLC): AVAIL (BO17704), a phase III randomized study. Chicago Multidisciplinary symposium in thoracic oncology 2008: 13–15 November 2008; Chicago. 2008, 101-
126.
Reily GJ, Miller VA: Vascular endothelial growth factor trap in non-small cell lung cancer. Clin Cancer Res. 2007, 13: 4623s-4626s. 10.1158/1078-0432.CCR-07-0544.CrossRef
127.
Massarelli E, Miller VA, Leighl NB, Rosen PJ, Albain KS, Hart LL, Melnyk O, Sternas L, Ackerman J, Herbst RS: Phase II study of the efficacy and safety of intravenous (iv) AVE0005 (VEGF Trap) given every 2 weeks in patients (pts) with platinum- and erlotinib-resistant adenocarcinoma of the lung (NSCLC) [abstract]. J Clin Oncol. 2007, 25 (Suppl 18): 7627-
128.
Aita M, Fasola G, Defferrari C, Brianti A, Bello MG, Follador A, Sinaccio G, Pronzato P, Grossi F: Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol. 2008, 68: 183-196. 10.1016/j.critrevonc.2008.05.002.PubMedCrossRef
129.
Hida T, Kozaki K, Muramatsu H, Masuda A, Shimizu S, Mitsudomi T, Sugiura T, Ogawa M, Takahashi T: Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res. 2000, 6: 2006-2011.PubMed
130.
Lilenbaum R, Socinski MA, Altorki NK, Hart LL, Keresztes RS, Hariharan S, Morrison ME, Fayyad R, Bonomi P: Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer. J Clin Oncol. 2006, 24: 4825-10.1200/JCO.2006.07.4773.PubMedCrossRef
131.
Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, Tye L, Selaru P, Chao RC, Scagliotti GV: Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol. 2008, 26: 650-656. 10.1200/JCO.2007.13.9303.PubMedCentralPubMedCrossRef
132.
Scagliotti GV, Novello S, Brahmer J, Govindan R, Rosell R, Belani C, Atkins J, Tye L, Chao R, Socinski MA: A phase II study of continuous daily sunitinib dosing in patients with previously-treated advanced non-small cell lung cancer (NSCLC). 12th World Conference on Lung Cancer, Seoul, Korea, September 2–6, 2007. J Thorac Oncol. 2007, 2 (Suppl 4): S470-10.1097/01.JTO.0000283418.42111.77.CrossRef
133.
Socinski MA: Current status and evolving role of sunitinib in non-small cell lung cancer. J Thorac Oncol. 2008, 3 (suppl 2): S119-S123.PubMedCrossRef
134.
Robert F, Sandler A, Schiller JH, Ilagan J, VerMeulen W, Harper K, Liu G, Tye L, Chao R, Traynor A: A phase I dose-escalation and pharmacokinetic (PK) study of sunitinib (SU) plus docetaxel (D) in patients (pts) with advanced solid tumors (STs) [abstract]. J Clin Oncol. 2007, 25 (Suppl 18): 3543-
135.
Gatzemeier U, Blumenschein G, Fosella F, Simantov R, Elting J, Bigwood D, Cihon F, Reck M: Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma [abstract]. J Clin Oncol. 2006, 24 (Suppl 18): 7002-
136.
Schiller JH, Flaherty KT, Redlinger M, Binger K, Eun J, Petrenciuc O, O'Dwyer P: Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: A phase I subset analysis [abstract]. J Clin Oncol. 2006, 24 (Suppl 18): 7194-
137.
Adjei AA, Molina JR, Hillman SL, Luyun RF, Reuter NF, Rowland KM, Jett JR, Mandrekar SJ, Schild SE: A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer: a north central cancer treatment group study [abstract]. J Clin Oncol. 2007, 25 (Suppl 18): 7547-
138.
Blumenschein G: Sorafenib in lung cancer: clinical developments and future directions. J Thorac Oncol. 2008, 3 (suppl 2): S124-S127.PubMedCrossRef
139.
Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, Spásová I, Belani CP, Bodrogi I, Gadgeel S, Kennedy SJ, Hou J, Herbst RS: Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol. 2007, 25: 4270-4277. 10.1200/JCO.2006.10.5122.PubMedCrossRef
140.
Schiller JH, Larson T, Ou SI, Limentani SA, Sandler AB, Vokes EE, Kim S, Liau KF, Bycott PW, Olszanski AJ: Efficacy and safety of axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II trial [abstract]. J Clin Oncol. 2007, 25 (Suppl 18): 7507-
141.
Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, Akerley W, Kelly K, Limentani SA, Crawford J, Reimers HJ, Axelrod R, Kashala O, Sheng S, Schiller JH: Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2006, 24: 5025-5033. 10.1200/JCO.2006.06.1853.PubMedCrossRef
142.
Davies AM, McCoy J, Lara PN, Gumerlock PH, Crowley J, Gandara DR, Southwest Oncology Group Thoracic Committee: Bortezomib + gemcitabine (gem)/carboplatin (carbo) results in encouraging survival in advanced non-small cell lung cancer (NSCLC): results of a phase II southwest oncology group (SWOG) trial (S0339)[abstract]. J Clin Oncol. 2006, 24 (Suppl 18): 7017-
143.
Davies AM, Lara PN, Mack PC, Gandara DR: Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res. 2007, 13 (Suppl 15): 4647s-4651s. 10.1158/1078-0432.CCR-07-0334.CrossRef
144.
Xu XC, Sozzi G, Lee JS, Lee JJ, Pastorino U, Pilotti S, Kurie JM, Hong WK, Lotan R: Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: Implications for lung cancer development. J Natl Cancer Inst. 1997, 89: 624-629. 10.1093/jnci/89.9.624.PubMedCrossRef
145.
Houle B, Rochette-Egly C, Bradley WE: Tumor-suppressive effect of the retinoic acid receptor beta in human epidermoid lung cancer cells. Proc Natl Acad Sci USA. 1993, 90: 985-989. 10.1073/pnas.90.3.985.PubMedCentralPubMedCrossRef
146.
Blumenschein GR, Khuri FR, von Pawel J, Gatzemeier U, Miller WH, Jotte RM, Le Treut J, Sun SL, Zhang JK, Dziewanowska ZE, Negro-Vilar A: Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. J Clin Oncol. 2008, 26: 1879-1885. 10.1200/JCO.2007.12.2689.PubMedCrossRef
147.
Ramlau R, Zatloukal P, Jassem J, Schwarzenberger P, Orlov SV, Gottfried M, Pereira JR, Temperley G, Negro-Vilar R, Rahal S, Zhang JK, Negro-Vilar A, Dziewanowska ZE: Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I. J Clin Oncol. 2008, 26: 1886-1892. 10.1200/JCO.2007.12.2614.PubMedCrossRef
Metadata
Title
Recent advances of novel targeted therapy in non-small cell lung cancer
Authors
Jed A Katzel
Michael P Fanucchi
Zujun Li
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2009
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-2-2

Other articles of this Issue 1/2009

Journal of Hematology & Oncology 1/2009 Go to the issue

Short report

A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China

Research

Radical cyberknife radiosurgery with tumor tracking: an effective treatment for inoperable small peripheral stage I non-small cell lung cancer

Case report

An unusual presentation of precursor T cell lymphoblastic leukemia/lymphoma with cholestatic jaundice: case report

Review

Emerging role of Garcinol, the antioxidant chalcone from Garcinia indica Choisy and its synthetic analogs

Review

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy

Research

Treatment of malignant tumors of the skull base with multi-session radiosurgery
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits